Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | FABP1 | P07148 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31682000 | 0.92 | SMN1; SMN2 (0.37) | SMN1; SMN2PKMCNR2GAAHDAC1 | |
| SCHEMBL24257977 | 0.89 | CNR2 (0.48) | SMN1; SMN2PKMCNR2GAAEGLN1 | |
| SCHEMBL22080340 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2PKMFABP1GAAHDAC1 | |
| SCHEMBL22029352 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMFABP1GAAHDAC1 | |
| SCHEMBL24257865 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMFABP1GAAHDAC1 | |
| SCHEMBL22080449 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMFABP1GAAHDAC1 | |
| SCHEMBL24257868 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMFABP1GAAHDAC1 | |
| SCHEMBL24257978 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMFABP1GAAHDAC1 | |
| SCHEMBL31682074 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2PKMGAAHDAC1EGLN1 | |
| SCHEMBL24257864 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMFABP1GAAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3893934-B1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-09-10 | — | — | EP | disclosed |
| US-20220048968-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2022-02-17 | — | — | US | disclosed |
| US-20200181223-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181223-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | SMN1; SMN2 1332/4885PKM 1743/4885CNR2 3357/4885 |
| US-20220048968-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | SMN1; SMN2 1332/4885PKM 1743/4885CNR2 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.